Rapid CommunicationDevelopment of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing
Keywords
COVID-19
Importins
Ivermectin
Minimal physiologically-based pharmacokinetic model
SARS-CoV-2
Pharmacokinetics
Pharmacometrics
Physiologically based pharmacokinetic modeling
Kinetics
Pharmacokinetic/pharmacodynamic (PK/PD) modeling
Cited by (0)
Funding: The study performed by Lifschitz and colleagues was partially supported by CONICET (Argentina), Universidad Nacional del Centro (Argentina), and Agencia Nacional de Promoción Científica y Tecnológica (PICT 08-00000-00817) Argentina.
Declarations of interest: None.
© 2020 Published by Elsevier Inc. on behalf of the American Pharmacists Association.